Contribution of Coagulases towards Staphylococcus aureus Disease and Protective Immunity by Cheng, Alice G. et al.
Contribution of Coagulases towards Staphylococcus
aureus Disease and Protective Immunity
Alice G. Cheng
1, Molly McAdow
1, Hwan K. Kim
1, Taeok Bae
2, Dominique M. Missiakas
1, Olaf
Schneewind
1*
1Department of Microbiology, University of Chicago, Chicago, Illinois, United States of America, 2Department of Microbiology and Immunology, Indiana University
School of Medicine-Northwest, Gary, Indiana, United States of America
Abstract
The bacterial pathogen Staphylococcus aureus seeds abscesses in host tissues to replicate at the center of these lesions,
protected from host immune cells via a pseudocapsule. Using histochemical staining, we identified prothrombin and fibrin
within abscesses and pseudocapsules. S. aureus secretes two clotting factors, coagulase (Coa) and von Willebrand factor
binding protein (vWbp). We report here that Coa and vWbp together are required for the formation of abscesses. Coa and
vWbp promote the non-proteolytic activation of prothrombin and cleavage of fibrinogen, reactions that are inhibited with
specific antibody against each of these molecules. Coa and vWbp specific antibodies confer protection against abscess
formation and S. aureus lethal bacteremia, suggesting that coagulases function as protective antigens for a staphylococcal
vaccine.
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Introduction
Staphylococcus aureus is a frequent cause of bacteremia, pneumo-
nia, skin and soft tissue infection as well as osteomyelitis and septic
arthritis [1]. The remarkable pathogenic potential of this organism
has been demonstrated over the past decade, with the rapid spread
of highly virulent, drug (methicillin)-resistant S. aureus strains
(MRSA) [2]. The search for protective immunity against invasive
S. aureus disease has been a research goal since the discovery of this
microbe [3]; this pursuit has not yet been successful and a
staphylococcal vaccine is currently not available [4].
Following entry into the blood stream of infected hosts, S. aureus
strains disseminate into tissues and seed abscesses [1]. Staphylo-
cocci multiply as a bacterial community at the center of these
lesions, separated from infiltrating immune cells by an amorphous
pseudocapsule [5]. Abscesses grow in size and eventually rupture,
providing for pathogen entry into blood circulation and dissem-
ination to uninfected tissues [5]. Previous studies identified cell
wall anchored surface proteins as contributors to abscess formation
and staphylococcal survival in infected tissues [5]. Some of these
molecules, for example IsdA and IsdB, promote staphylococcal
uptake of iron from host hemoproteins [6], whereas others, e.g.
AdsA and protein A (SpA), suppress host immune responses [7,8].
The products of genes that contribute towards abscess
formation have also been examined for their protective antigen
attributes. Antibodies against IsdA or IsdB generate protection
against staphylococcal replication within infected tissues and
reduce the incidence of S. aureus abscess formation in mice [9].
The possibility that IsdB may raise vaccine protection from
staphylococcal diseases in humans is currently being tested [10].
Antibodies against SpA neutralize B cell superantigen and
antiphagocytic attributes of this immunoglobulin-binding molecule
and enable clearance of the invading pathogen in immunized hosts
[11]. We consider the effects of IsdA-, IsdB- or SpA-specific
antibodies on abscess formation to be indirect; these surface
proteins do not appear to instruct the host of forming the
characteristic lesions for pathogen replication. Nevertheless,
previous work demonstrated that staphylococcal genes involved
in abscess formation can be identified through specific genetic
lesions as well as immune responses against their encoded products
[5].
In an effort to explore secreted proteins for vaccine develop-
ment and abscess formation, we examine here the coagulases of S.
aureus. Coagulase (Coa) has been studied for more than 100 years
[12,13] and is secreted by virtually all S. aureus isolates [14,15]. N-
terminal and central parts of Coa display sequence variation,
which has been exploited for the classification of strains [16,17].
Coagulase production is used as a diagnostic test, differentiating S.
aureus isolates from commensal staphylococci, for example S.
epidermidis [18]. During host infection, Coa conformationally
activates the central coagulation zymogen, prothrombin, thereby
triggering the cleavage of fibrinogen to fibrin [19]. The crystal
structure of the active complex revealed binding of the D1 and D2
domains to prothrombin and insertion of the Ile
1-Val
2 N-terminus
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16 pocket of prothrombin, inducing a functional
active site in the zymogen through conformational change [20].
Exosite I of a-thrombin, the fibrinogen recognition site, and
proexosite I on prothrombin are blocked by the D2 of Coa [20].
Nevertheless, association of the tetrameric (Coa?prothrombin)2
complex enables fibrinogen binding at a new site with high affinity
[19]. This model can explain the coagulant properties and efficient
fibrinogen conversion by coagulase [19]. Fibrinogen is a large
glycoprotein (Mr,340,000), formed by three pairs of Aa-, Bb-,
and c-chains covalently linked to form a ‘‘dimer of trimers,’’ where
A and B designate the fibrinopeptides released by thrombin
cleavage [19]. The elongated molecule folds into three separate
domains, a central fragment E that contains the N-termini of all six
chains and two flanking fragments D formed mainly by the C-
termini of the Bb- and c-chains. These globular domains are
connected by long triple-helical structures. Coa?prothrombin
complexes, which convert human fibrinogen to the self-polymer-
izing fibrin, are not targeted by circulating thrombin inhibitors
[19], allowing coagulase to bypass the physiological regulatory
steps of blood coagulation pathways [21].
S. aureus secretes a second coagulase, designated von Willebrand
factor-binding protein (vWbp) [22,23]. The D1 and D2 domains
of vWbp display 30% amino acid identity with the corresponding
domain of coagulase and also associate with prothrombin,
activating the zymogen and promoting cleavage of fibrinogen to
fibrin [24]. Frykberg and colleagues reported that vWbp
preferentially activates human prothrombin, whereas Coa coag-
ulase indiscriminately clots human, rabbit and mouse plasma [23].
The contributions of isogenic S. aureus coa and vWbp mutants
towards abscess formation have not yet been studied. Further, the
protective antigen attributes of isolated Coa and vWbp towards
abscess formation and/or staphylococcal septicemia are still
unknown.
Results
Coagulation factors and coagulases within
staphylococcal abscesses
Previous work established the mouse renal abscess model,
whereby 1610
7 CFU of the human clinical isolate S. aureus
Newman [25] are injected into the blood stream of BALB/c mice
[26]. Forty-eight hours following infection, mice develop dissem-
inated abscesses in multiple organs, detectable by light microscopy
of thin-sectioned, hematoxylin-eosin stained kidney tissue initially
as an accumulation of polymorphonuclear leukocytes (PMNs) with
few bacteria [5]. By day 5 of infection, abscesses increase in size
and enclose a central population of staphylococci (staphylococcal
abscess community - SAC), surrounded by a layer of eosinophilic,
amorphous material (the pseudocapsule) and a large cuff of PMNs
(Fig. 1) [5]. Histopathology reveals massive necrosis of PMNs in
proximity to the staphylococcal nidus at the center of abscess
lesions as well as a mantle of healthy phagocytes. At later time
intervals, SACs increase and abscesses rupture, releasing necrotic
material and staphylococci into the bloodstream. A new round of
abscess formation is initiated, eventually precipitating a lethal
outcome of infections [5].
We sought to localize host factors within abscess lesions and
used serial thin-sections of kidneys from mice that had been
infected for five days with S. aureus Newman for immune-
histochemical staining experiments with antibodies against pro-
thrombin or fibrinogen (Fig. 1). Staining of renal tissues with
prothombin-specific antibodies led to the accumulation of brown
pigment in the area of the eosinophilic pseudocapsule (black box in
Fig. 1A, C) as well as in the periphery of abscess lesions (green
box). Staining with fibrinogen/fibrin specific antibodies produced
diffuse brown pigment deposits throughout the lesion with more
intense pigment accumulation in the periphery of the abscess
(Fig. 1B, D). As a control, staining with secondary antibodies alone
did not lead to histochemical deposition of brown pigments in
renal tissues (Fig. S1). These results suggest that both prothrombin
and fibrinogen/fibrin accumulate within staphylococcal abscess
lesions.
Rothfork and colleagues studied the contribution of fibrinogen
towards staphylococcal pathogenesis [27]. Ancrod-mediated cleav-
age of fibrinogen followed by removal of fibrin fragments via the
reticulo-endothelial system is known to trigger fibrinogen depletion
[28], and this condition reduced the staphylococcal burden in a
murine air pouch model [27]. One plausible explanation for the
observations of Rothfork and colleagues is that secreted coagulases
contribute to the pathogenesis of staphylococcal infections in the
presence fibrinogen but not in its absence.
To localize coagulases in abscess lesions, thin-sectioned renal
tissue of mice infected for 5 days with S. aureus Newman was
stained by immuno-histochemistry with affinity purified Coa- or
vWbp-specific rabbit antibodies (Fig. 1E–H). We observed intense
Coa staining in the pseudocapsule surrounding SACs and in the
periphery of abscess lesions, i.e. the fibrin capsule bordering
uninfected tissue (Fig. 1E, G). vWbp staining occurred throughout
abscess lesions, but also with accumulation at the periphery
(Fig. 1F, H). Together these data suggest that the eosinophilic
pseudocapsule of staphylococcal abscesses harbors prothrombin
and fibrinogen, which co-localize with Coa. At the periphery of
abscess lesions, Coa, vWbp, prothrombin as well as fibrinogen/
fibrin are co-localized. These observations prompted us to further
investigate whether Coa and vWbp are crucial contributors to the
establishment of abscesses by triggering prothombin-mediated
conversion of fibrinogen to fibrin.
S. aureus coa and vWbp contribute to the clotting of
mouse blood
The coa and/or vWbp genes on the chromosome of S. aureus
Newman were deleted by allelic replacement [29](Fig. 2A). Two
complementing plasmids, pcoa and pvWbp, were generated by
cloning coa or vWbp structural genes as well as their upstream
promoter sequences into pOS1 [30]. Plasmids were electroporated
into staphylococci and their continued replication selected on
Author Summary
Clinical isolates of the human pathogen Staphylococcus
aureus secrete coagulase (Coa), a polypeptide that binds to
and activates prothrombin, thereby converting fibrinogen
to fibrin and promoting clotting of plasma or blood.
Another secreted coagulase, designated von-Willebrand
factor binding protein (vWbp), catalyzes a similar reaction.
Staphylococcal binding to fibrinogen or fibrin is an
important attribute of disease pathogenesis, which leads
to the formation of abscesses and bacterial persistence in
host tissues. We report here that Coa and vWbp are
essential for S. aureus strain Newman abscess formation
and persistence in host tissues. Antibodies directed against
Coa or vWbp prevent coagulase binding to prothrombin
or fibrinogen and confer protection against challenge with
S. aureus Newman or the methicillin-resistant S. aureus
isolate USA300 LAC in mouse models of abscess formation
or lethal sepsis. These results suggest that coagulases may
be used as vaccine antigens to elicit antibodies that
protect humans against S. aureus infections.
Coagulases as Protective Antigens
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expression of coagulases with specific antibodies, we observed Coa
secretion by wild-type S. aureus as well as the DvWbp strain, but not
by Dcoa or Dcoa/DvWbp variants (Fig. 2B). The phenotypic defect
of Dcoa and Dcoa/DvWbp mutants was restored by electroporation
with pcoa but not by pvWbp (Fig. 2B). Similarly, secretion of vWbp
was observed in S. aureus Newman (wild-type) as well as Dcoa
mutant cultures, but not in DvWbp or Dcoa/DvWbp variants
(Fig. 2B). This defect was restored by electroporation with pvWbp,
but not by pcoa.
Figure 1. Localization of prothrombin, fibrinogen, coagulase (Coa), and von Willebrand factor binding protein (vWbp) in
staphylococcal abscesses. BALB/c mice infected by intravenous inoculation with 1610
7 CFU S. aureus Newman were killed 5 days post infection.
Kidneys were removed and serial thin-sections stained by immunochemistry using rabbit antibodies (a) specific for mouse prothrombin (A, C), mouse
fibrinogen/fibrin (B, D), S. aureus Coa (E, G) or S. aureus vWbp (F, H). Antibody deposition is revealed as brown pigment in tissues counterstained with
hematoxylin. Displayed images are representative of three sampled kidneys. Panels C, D, G, and H illustrate antibody staining within a single abscess
analyzed as four sequential sections, enlarged from an area in panels A, B, E, and F that is defined by a box with white margins. In panel C, the black
box designates the area of the eosinophilic pseudocapsule surrounding the staphylococcal abscess community (SAC), which is marked by the black
arrowhead. The SAC is surrounded by a zone of dead PMNs (white box), a zone of apparently healthy PMNs (red box), and a rim of necrotic PMNs
(green box), separated through an eosinophilic layer from healthy kidney tissue.
doi:10.1371/journal.ppat.1001036.g001
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mutant staphylococci in mouse blood. Clotting of blood is
effectively inhibited by hirudin (lepirudin) [32], a 65 residue
peptide from leech that forms a 1:1 complex with thrombin,
thereby blocking proteolytic conversion of fibrinogen to fibrin
[33]. Inoculation of fresh lepirudin-treated mouse blood with S.
aureus Newman triggered clotting in less than 12 hours, whereas
mock infected blood remained without clots for more than
48 hours (Fig. 2C). Using this assay, we observed that staphylo-
coccal variants lacking coagulase activity displayed delays in
Figure 2. Staphylococcus aureus coa and vWbp mutants display defects in blood clotting. (A) Diagram illustrating the primary translational
product of coa and vWbp including signal peptide (S), the D1 and D2 domain for prothrombin binding, a domain of unknown function, von
Willebrand factor (vWF) binding site on vWbp, and the fibrinogen binding repeats (R) of Coa. Numbers indicate amino acid residues. (B) Culture
supernatants from S. aureus Newman (wild-type) or isogenic variants lacking coa (Dcoa), vWbp (DvWbp) or both genes (DvWbp/Dcoa) were examined
by immunoblotting with antibodies specific for Coa (aCoa) or vWbp (avWbp). For complementation studies, plasmids expressing the wild-type alleles
of coa (pcoa)o rvWbp (pvWbp) were electroporated into staphylococcal strains and subsequently analyzed by immunoblotting. (C) Lepirudin-treated
mouse blood was mock treated or infected with S. aureus Newman or its isogenic coagulase variants and incubated for up to 48 hours at 25uC. Tubes
were tilted to assess coagulation. Data are representative of four independent determinations.
doi:10.1371/journal.ppat.1001036.g002
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double mutant, Dcoa/DvWbp, was unable to clot mouse blood.
These defects were complemented by electroporation with
plasmids pvWbp as well as pcoa. Inoculation of S. aureus strains
into lepirudin-treated human blood produced similar results: the
DvWbp strain caused a small reduction in clotting time, the Dcoa
strain displayed a more severe defect and the DvWbp/Dcoa mutant
altogether failed to coagulate blood (Fig. S2A). Taken together,
these data indicate that the two coagulases, Coa and vWbp,
contribute both to the ability of S. aureus Newman to clot mouse or
human blood, whereas the double mutant strain, DvWbp/Dcoa,
cannot elaborate coagulase activity.
Coa and vWbp are required for the pathogenesis of S.
aureus disease in mice
To analyze the virulence contributions of coagulases, we first
examined staphylococcal survival in lepirudin-treated blood. S.
aureus Newman was not killed in mouse blood (Fig. 3A). In
contrast, the mutant strains, Dcoa (P=0.0470), DvWbp
(P=0.0586), and Dcoa/DvWbp (P=0.0282), displayed a reduction
in CFU after 30 min incubation in mouse blood (Fig. 3A).
Interestingly, the double mutant did not display an additive defect
in blood survival, and introduction of either pcoa or pvWbp
restored the wild-type phenotype (Fig. 3A). When analyzed in
human blood, the DvWbp variant (P=0.146) exhibited only a small
defect in survival, and not to the same degree as the Dcoa mutant
(P=0.00790, Fig. S2B). The mutant lacking both coagulases,
DvWbp/Dcoa (P=0.000971), suffered the largest reduction in
CFU. The addition of either pvWbp or pcoa to DvWbp/Dcoa
staphylococci restored their survival in human blood to wild-type
levels (Fig. S2B). These findings suggest that both coagulases, Coa
and vWbp, contribute to staphylococcal survival in human and
mouse blood.
Staphylococcal bacteremia is a frequent cause of human
morbidity and mortality in hospital settings [34]. We sought to
ascertain whether coagulases are required for lethal challenge of
BALB/c mice. Following intravenous injection of 1610
8 CFU S.
aureus Newman, all infected animals succumbed to infection within
24 hours (Fig. 3B). Animals infected with single gene mutants, Dcoa
(P,0.0001) or DvWbp (P,0.0001), each displayed a significant
delay in time-to-death (Fig. 3B). The double mutant strain was
significantly more impaired than mutants with single deletions
(wild-type vs. DvWbp/Dcoa,P ,0.0001; Dcoa vs. DvWbp/Dcoa,
P,0.0001; and DvWbp vs. DvWbp/Dcoa P,0.0001) (Fig. 3B).
Introduction of pvWbp-coa, a plasmid providing for the expression
of both coagulase genes, into DvWbp/Dcoa staphylococci restored
the secretion of Coa and vWbp as well as the virulence of the
mutant strain in the lethal bacteremia model to the same level as
the wild-type parent, S. aureus Newman (Fig. S3A, B).
We next analyzed abscess formation in renal tissues of infected
mice and observed that coa variants, in comparison with wild-type
staphylococci, were impaired in their ability to replicate and
persist in these tissues over 15 days, whereas at earlier time points,
i.e. day 5, no significant defects were observed (Table 1, Fig. 3C–
R). The vWbp (Fig. 3D, F and L, N), and coa (Fig. 3G, I and O,Q)
mutants both continued to form abscesses, albeit that bacterial
load, the overall size of staphylococcal abscess communities and
the amount of immune cell infiltrates was somewhat reduced in
these variants (Fig. 3 and Table 1). Dcoa mutants were more
attenuated in virulence than DvWbp,a scoa variants, but not
DvWbp, displayed reduced bacterial load by day 15. In contrast,
deletion of both coagulase genes caused a dramatic defect; Dcoa/
DvWbp double mutants were unable to form abscesses or persist in
infected tissues (Table 1, Fig. 3H, J and P, R). Thus, Coa and
vWbp are important for the pathogenesis of S. aureus infections,
whether measured as staphylococcal survival in the bloodstream,
lethal bacteremia or the ability of S. aureus to form abscesses and
persist in host tissues.
Antibodies against coagulases affect staphylococcal
clotting of blood
Recombinant His6-Coa and His6-vWbp were purified by
affinity chromatography on Ni-NTA (Fig. 4A), emulsified in
adjuvant and injected into rabbits to raise specific antibodies that
were purified on affinity matrices harboring recombinant protein.
Antibodies directed against Coa preferentially bound to Coa, not
to vWbp (Fig. 4B). The reciprocal was observed for antibodies
directed against vWbp (Fig. 4B). When added to lepirudin-treated
mouse blood infected with S. aureus Newman, antibodies directed
against Coa, vWbp or Coa and vWbp each interfered with the
coagulation of blood (Fig. 4C). As control, the irrelevant V10
antibody, which provides protection against Yersinia pestis type III
injection [35], had no effect (Fig. 4C). Similar results were
obtained with human blood; avWbp and aCoa each impeded
clotting, however a combination of antibodies directed against
both coagulases effectively blocked S. aureus coagulation (Fig. S4A).
To examine the role of antibodies on isolated Coa or vWbp, we
purified recombinant, functionally active proteins [20] that were
added to lepirudin treated mouse or human blood. Coa or vWbp
treated mouse blood coagulated in less than 30 minutes (Fig. 4D). As
control, treatment with the irrelevant V10 antibody did not affect
clotting. Antibodies directed against Coa or vWbp delayed the
clotting of mouse blood with the homologous coagulase. Surpris-
ingly, inhibition occurred also for antibodies raised against
heterologous coagulases albeit at a reduced level (Fig. 4D). Similar
phenomena were observed when purified Coa and vWbp were
incubatedwithhuman blood(Fig.S4B).Thus,althoughwe observed
small amounts of cross-reactivity between Coa and vWbp-specific
antibodies by ELISA and immunoblot (Fig. 4B), some cross-
inhibition of coagulases appears to occur. We surmise, but do not
yet know, that cross-reacting conformational epitopes in coagulase
complexes,formed betweenCoa or vWbpand prothrombin,maybe
recognized by antibodies that can be derived with both antigens.
Antibodies that block association between coagulases
and prothrombin or fibrinogen
Association of Coa and vWbp with prothrombin as well as
fibrinogen was measured by SPR (Fig. S5). Using a range of
concentrations, we calculated the dissociation constant (KD) for
Coa and prothombin (5.0 nM) or fibrinogen (33 nM) as well as for
vWbp and prothombin (98 nM) or fibrinogen (271 nM). The
ability of vWbp to bind fibrinogen had hitherto not been reported
in the literature. The KD for the coagulase?prothrombin
interaction is lower than the reported affinity for the D1D2
domain alone [36]; we currently do not appreciate the basis for
this difference. Enzyme-linked immunosorbant assays (ELISA)
were used to assess whether aCoa and avWbp antibodies interfere
with the association between coagulases and clotting factors. Coa
and vWbp were coated onto ELISA plates and incubated with
specific antibodies at variable concentrations. Association or Coa
or vWbp with clotting factors was detected by incubating wells
with either prothrombin or fibrinogen and subsequently probing
with primary and secondary HRP-conjugate antibodies. A
significant dose-dependent decrease in the formation of coagula-
se?prothrombin complexes was observed in the presence of Coa-
specific antibodies (Fig. 5A). In contrast, although specific
antibodies reduced the association between Coa and fibrinogen,
Coagulases as Protective Antigens
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the nature of the C-terminal repeat structure of this protein, as a
similar phenomenon was not observed for vWbp lacking such C-
terminal repeat structure (Fig. 5B). Specific antibodies blocked the
associations between vWbp and prothrombin or fibrinogen in a
dose-dependent manner (Fig. 5C, D). These findings corroborate
results from the coagulation assays and demonstrate that specific
polyclonal antibodies block the ability of Coa or vWbp to form
active complexes with prothrombin that then act on fibrinogen
(Fig. 3A).
To test whether specific antibodies can also block enzymatic
activity, we measured the ability of Coa?prothrombin or
vWbp?prothrombin complexes to cleave S-2238, a surrogate for
the cleavage of fibrinogen to fibrin (Fig. 5E, F). The addition of
specific antibodies to Coa?prothrombin or vWbp?prothrombin
reduced the ability of enzyme complexes to convert fibrinogen
substrate to product (Km) as well as the maximum velocity with
which such reaction occurs (Vmax) (data not shown). Fig. 5E
displays Coa?prothrombin enzymatic activity at 1 mM S-2238.
Addition of aCoa (P=0.00155), but not of avWbp (P=0.129),
reduced substrate cleavage. Interestingly, vWbp?prothrombin
activity (Fig. 5F) was impeded by both specific vWbp antibodies
(P=0.0123) and by cross-reacting Coa antibodies (P=0.0421).
Thus, antibodies directed against Coa or vWbp can neutralize the
pathophysiological functions of these secreted coagulases.
Antibodies against coagulases provide protection
against staphylococcal disease
To test antibody reagents for possible vaccine protection against
lethalbacteremia,weinjected affinitypurified IgG(5 mg kg
21 body
weight) into the peritoneal cavity of mice. Twenty-four hours later,
animals were injected with a suspension of 1610
8 CFU S. aureus
Newman in PBS into the retro-orbital plexus. Monitoring animals
over time, we observed that antibodies directed against vWbp led to
an increase in time-to-death (avWbp vs. aV10, P=0.0005) and to
10% survival, as compared to animals that had received irrelevant
aV10 antibodies and died within 12–48 hours (Fig. 6A). Antibodies
against Coa increased the time-to-death even further (P=0.0003)
(Fig. 6A). A mixture of both antibodies (aCoa/avWbp each at
2.5 mg kg
21) also provided protection but did not improve survival
or time-to-death as compared to anti-Coa (aCoa/avWbp vs. aV10,
P,0.0001; aCoa/avWbp vs. avWbp, P=0.0886; aCoa/avWbp
vs. aCoa, P=0.836). These data are likely attributable, at least in
part, to the cross-reactivity of coagulase antibodies and to the
unique attribute of S. aureus Newman, which secretes abundant
amounts of Coa (Fig. 4D, 5E, F).
Table 1. Virulence of staphylococcal Dcoa, DvWbp, and DvWbp/coa variants.
S. aureus strain Staphylococcal load in kidney tissue* Abscess formation*
alog10 CFU g
21
kidney tissue
bSignificance
(P-value)
cReduction in
alog10 CFU g
21
dNumber of abscesses per
kidney
eSignificance
(P-value)
Day 5 post challenge
wild-type 6.0360.89 – – 2.360.6 –
Dcoa 5.5361.77 0.375 0.49 1.160.4 0.190
DvWbp 5.2460.98 0.085 0.78 1.760.6 0.436
DvWbp/coa 4.9060.79 0.004 1.39 0.760.3 0.062
Day 15 post challenge
wild-type 5.3860.83 – – 3.061.2 –
Dcoa 4.0260.83 0.007 1.35 1.460.4 0.276
DvWbp 5.1461.47 0.068 0.24 1.660.3 0.328
DvWbp/coa 3.3061.65 0.005 2.08 0.560.1 0.015
*BALB/c mice (n=10) were challenged by intravenous inoculation with 1610
7 colony forming units (CFU) S. aureus Newman or isogenic variants in coagulases (Dcoa,
DvWbp,a n dDvWbp/coa). Five days later, animals were killed and both kidneys removed. One kidney was fixed in formaldehyde, embedded in paraffin, thin sectioned,
hemaotoxylin-eosin stained and four saggital sections per kidney were analyzed for abscess formation. The other kidney was homogenized in PBS buffer, homogenate
spread on agar medium for colony formation, and staphylococcal load enumerated as CFU. Data from two separate experiments are averaged.
aMeans of staphylococcal load calculated as log10 CFU g
21 in homogenized renal tissues 4 days following infection in cohorts of 10 BALB/c mice per immunization.
Standard error (6SE) is indicated.
bStatistical significance was calculated with the unpaired two-tailed Students t-test and P-values recorded; P-values ,0.05 were deemed significant.
cReduction in bacterial load calculated as log10 CFU g
21.
dHistopathology of thin-sectioned, hematoxylin-eosin stained kidneys from ten animals; the average number of abscesses per kidney was recorded and averaged again
for the final mean (6SEM).
eStatistical significance was calculated with the non-parametric Mann-Whitney test and P-values recorded; P-values ,0.05 are significant.
doi:10.1371/journal.ppat.1001036.t001
Figure 3. Contributions of coa and vWbp to bacterial survival in blood and S. aureus induced lethal bacteremia or renal abscess
formation in mice. (A) S. aureus Newman as well as its variants Dcoa, DvWbp or DvWbp/Dcoa with or without complementing plasmids (pcoa and
pvWbp) were incubated with lepirudin anticoagulated mouse blood for 30 minutes and bacterial survival assessed by colony formation on agar
plates. Data were generated from three separate trials. (B) Cohorts of 10 mice were injected into the retro-orbital plexus with 1610
8 CFU of S. aureus
Newman (wild-type) as well as the Dcoa, DvWbp or DvWbp/Dcoa variants. Animal survival over time was recorded over 10 days. (C–R) Mice were
injected into the retro-orbital plexus with 1610
7 CFU of S. aureus Newman (C, E and K, M), DvWbp (D, F and M, L), Dcoa (G, I and O,Q) or DvWbp/Dcoa
variants (H, J and P, R). Animals were killed 5 (C–J) or 15 days following challenge (K–R). Following necropsy, renal tissues were assessed for
staphylococcal load (Table 1) and thin-sectioned, hematoxylin-eosin stained samples examined for histopathological features of abscess formation.
Animal data are representative of two independent experiments.
doi:10.1371/journal.ppat.1001036.g003
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mice against other S. aureus isolates, USA300 LAC, a highly
virulent and wide-spread clinical isolate responsible for the recent
epidemic of CA- MRSA infections, was used as a challenge strain
[37]. As compared to the anti-V10 immunized control animals,
passive transfer of anti-Coa (P=0.0007) or anti-vWbp (P=0.0017)
protected mice against lethal bacteremia with USA300 LAC
(Fig. 6B). Animals that received 2.5 mg kg
21 of both anti-Coa and
anti-vWbp displayed improved survival (P,0.0001, Fig. 6B).
Thus, antibodies against each of the two coagulases generate
protection against challenge with S. aureus strains Newman and
USA300 LAC. A synergistic effect of anti-Coa and anti-vWbp
antibodies was observed for challenge experiments involving
USA300 LAC, but not for strain Newman.
To examine passive immunization for protection against
staphylococcal abscess formation, we injected purified antibodies
(5 mg kg
21 body weight) into the peritoneal cavity of mice and
monitored abscess formation five days after intravenous challenge
with 1610
7 CFU S. aureus Newman. Antibodies against vWbp did
not lead to a significant reduction in staphylococcal load
(P=0.3554) but reduced the number of abscess lesions (Table 2).
These lesions harbored smaller abscess communities and reduced
PMN infiltrates as compared to mock immunized mice (Fig. 7A, C
and B, D). Antibodies against Coa reduced the staphylococcal load
(P=0.042) as well as the number of lesions (P=0.0303); abscess
lesions with staphylococcal communities at the nidus of large PMN
infiltrates were not detected (Fig. 7E, G and Table 2). Animals that
received both antibodies, aWbp and aCoa, displayed an even
greater reduction in staphylococcal load (P=0.013) and in the
abundance of abscess lesions (P=0.0043) (Fig. 7F, H and Table 2).
Together these data indicate that antibodies against coagulases,
administered by passive immunization, protect mice against
abscess formation and enable clearance of the invading pathogen
from host tissues. Antibodies against vWbp have a smaller
contribution to vaccine protection, in agreement with the finding
that vWbp does not play the same critical role as Coa during the
pathogenesis of S. aureus infections in mice.
Coagulases function as protective antigens for
staphylococcal infections
Poly-histidine tagged CoA and vWbp were purified from E. coli
and used as subunit vaccine antigens. Proteins (50 mg emulisified
in CFA or IFA) were injected into naı ¨ve BALB/c mice on day 0
(CFA) or 11 (IFA). Animals were challenged on day 21 by
intravenous inoculation of S. aureus Newman. Five control animals
were bled at the time of challenge and serum antibody titers
against vaccine antigens were determined by ELISA (Table 3).
Animals were killed five or fifteen days following challenge.
Staphylococcal load and histopathology of abscess lesions were
analyzed (Fig. 8). Immunization with Coa reduced the bacterial
load by day 5 (P=0.018, PBS mock vs. Coa) and day 15
(P=6.42610
26, PBS mock vs. Coa, see Table 3). Coa vaccine also
diminished the number of infectious lesions that formed in kidney
tissues [mock vs. Coa, P=0.01 (day 5) and P=0.005 (day 15)]
(Table 3). Of note, none of the Coa-immunized mice developed
typical abscess lesions (Fig. 8A, C and E, G). On occasion we
observed small accumulations of PMNs that were not associated
with staphylococcal abscess communities (Fig. 8E, G). Immuniza-
tion with vWbp did not significantly reduce staphylococcal load on
day 5 (P=0.055, PBS mock vs. vWbp) but did so by day 15
(P=4.25610
25, PBS mock vs. vWbp). The total number of
abscess lesions was not significantly reduced on day 15 (P=0.057,
PBS mock vs. vWbp), however, the architecture of abscesses had
changed following immunization with vWbp. We failed to detect
staphylococcal communities at the center of abscesses and instead
observed PMN infiltrations (Fig. 8B, D). The combination vaccine,
vWbp-Coa, further reduced the number of inflammatory cells in
kidney tissues and infected animals did not display abscess lesions
on day 5 or 15 (Table 3).
Figure 4. Antibodies against Coa and vWbp block the clotting
of blood by staphylococcal coagulases. (A) His6-Coa and His6-
vWbp were purified by affinity chromatography from E. coli and
analyzed on Coomassie-stained SDS-PAGE. (B) Rabbit antibodies were
raised against His6-Coa or His6-vWbp, affinity purified and analyzed by
ELISA for immune reactivity with purified coagulases. Data are averaged
from three independent experimental determinations. (C) Lepirudin-
treated mouse blood was treated with PBS (mock), irrelevant antibodies
(aV10) or antibodies directed against Coa (aCoa), vWbp (avWbp) or
both coagulases (aCoa/avWbp) prior to infection with S. aureus
Newman and incubation for 48 hours at 25uC. (D) Lepirudin-treated
mouse blood was treated with antibodies as above. Blood samples
were then incubated with functionally active Coa or vWbp and
coagulation time recorded.
doi:10.1371/journal.ppat.1001036.g004
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(5610
6 CFU) and lethal (5610
7 CFU) doses of USA300 LAC. For
the CA-MRSA strain, mice immunized with only Coa or vWbp
were not protected from disease, however animals receiving both
antigens had significantly reduced abscess formation on day 5
(P=0.022, PBS mock vs. vWbp/Coa) or day 15 (P=0.014) (Fig.
S6, Table 4). These animals also displayed reduced staphylococcal
load in renal tissues by day 15 (P=0.00067) (Fig. S6, Table 4).
Following lethal challenge with USA300 LAC, mice that had been
immunized with Coa survived longer than mock immunized
animals (P=0.0040, PBS mock vs. Coa) (Fig. S7). Further, animals
that had been immunized with both antigens survived longer than
those that received only vWbp or Coa alone (P,0.0001, vWbp vs.
double, P=0.0022, Coa vs. double) (Fig. S7). In summary,
immunization with both coagulases, Coa and vWbp, generates
protection in mice against abscess formation and lethal bacteremia
caused by MSSA strain Newman or the CA-MRSA isolate
USA300 LAC.
Discussion
The vast majority of clinically relevant S. aureus strains secrete
coagulase and vWbp [14,23]. Early work reported important
contributions of coagulase to the pathogenesis of staphylococcal
infections [15,38]. More recent investigations used molecular
genetic tools to generate isogenic coa mutations, however the
resulting variants of S. aureus 8325-4, a laboratory strain that
secretes relatively little coagulase, did not display virulence
phenotypes in endocarditis, skin abscess and mastitis models in
mice [16,39]. Generating isogenic variants of S. aureus Newman, a
Figure 5. Biological effects of antibodies directed against staphylococcal coagulases. (A) Purified Coa and vWbp were coated onto ELISA
Nunc maxisorp plates and the degree of (A, C) prothrombin or (B, D) fibrinogen binding was measured. To assess antibody perturbation of these
interactions, specific or control (aV10) antibodies were added at 1:10 dilutions. (E, F) Purified active Coa or vWbp was incubated in a 1:1 molar ratio
with human prothrombin. Enzymatic activity of these complexes was assessed by monitoring the rate of S-2238 cleavage (a chromogenic substrate
provided in excess). The assay was repeated in presence of specific- or cross-reacting antibodies. Data were normalized to the % average activity
without inhibition. All data represent averages of three independent trials. Single asterisks denote statistical significance P,0.05, two asterisks
indicate P,0.01 calculated with the two-tailed student’s t-test.
doi:10.1371/journal.ppat.1001036.g005
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defects in both coagulase genes, coa and vWbp, display virulence
defects in three mouse models for staphylococcal disease: survival
in blood, lethal bacteremia and renal abscess formation. Of note,
S. aureus Newman secretes large amounts of coagulase due to a
point mutation in the two-component regulatory gene saeS [40].
This may explain why S. aureus Newman mutants lacking only one
gene, coa or vWbp, displayed defects in each of the three models,
albeit that the observed phenotypes are weaker than those of the
double mutant (Fig. 2 and 3). Antibodies that had been raised
against Coa or vWbp perturb the pathogenesis of S. aureus
Newman infections in a manner mirroring the impact of
corresponding gene deletions. By binding to Coa or vWbp antigen
and blocking their association with clotting factors, antibodies
prevent the formation of Coa?prothrombin or vWbp?prothrombin
complexes. Passive transfer studies revealed protection of exper-
imental animals against staphylococcal abscess formation and
lethal bacteremia by Coa and vWbp antibodies, in agreement with
the general hypothesis that the neutralization of coagulases may
generate immunity from staphylococcal disease. Antibodies against
both Coa and vWbp were required to protect mice against
challenge with the highly virulent CA-MRSA strain USA300
LAC. These data illustrate the crucial contribution of staphylo-
coccal coagulation towards disease pathogenesis and document
that both coagulases, Coa and vWbp, may be important antigens
in the development of a vaccine that can protect against the
current CA-MRSA epidemic.
Earlier work, examining the ability of vWbp to coagulate mouse
blood, suggested that this coagulase is less effective in murine
blood than Coa, but displays high clotting activity in human blood
[23]. Experiments in Fig. 3D suggest that purified Coa and vWbp
were both able to coagulate mouse blood at a similar rate. By
comparison, both staphylococcal coagulases seemed even more
effective coagulating human blood (Fig. S4). Nevertheless, DvWbp
mutants displayed a smaller virulence defect than Dcoa variants
(Table 1 and Fig. 2) and vWbp immunization provided less
protection for mice than Coa vaccines (Tables 2 and 3), suggesting
that the two coagulases do not fulfill identical functions during the
pathogenesis of S. aureus infections in mice.
What is the specific purpose of blood clotting to induce
staphylococcal disease? Expression of Coa and vWbp in abscess
lesions as well as their striking distribution in the eosinophilic
pseudocapsule surrounding staphylococcal abscess communities
suggests that secreted coagulases contribute to the establishment of
these lesions. This hypothesis was tested and mutants lacking both
coagulases are indeed defective in abscess formation and in the
establishment of lethal bacteremia. The reciprocal test, neutraliz-
ing the function of coagulases with specific antibodies, produced a
similar effect. Earlier work by Rothfork and colleagues already
demonstrated the requirement of fibrinogen for the pathogenesis
of staphylococcal infections [27]. Based on these observations, we
propose that the clotting of fibrin by secreted coagulases is a
critical event in the establishment of staphylococcal communities
surrounded by eosinophilic pseudocapsules and subsequent
abscess development. As the establishment of abscess lesions can
be blocked with antibodies specific for coagulases, these data
further corroborate the concept that Coa and vWbp should be
considered for staphylococcal vaccine development.
Coa and vWbp appear to be the only coagulases of S. aureus, i.e.
factors capable of catalytically converting fibrinogen to fibrin and
generating clots, because DvWbp/Dcoa mutants are unable to
coagulate mouse and human blood. Early studies described
clumping factor activity, the ability of isolated staphylococci
(without secreted factors) to clot fibrin [41]. Clumping factor
activity has been attributed to two cell wall anchored surface
proteins, ClfA and ClfB, each of which binds to fibrinogen [42,43].
While ClfA and ClfB specifically bind to fibrinogen, this binding
does not precipitate fibrinogen cleavage and/or fibrin clot
formation [44]. clfA and clfB mutants display defects in survival
in blood, resistance to phagocytosis and reduced staphylococcal
load in organ tissues [45,46]; nevertheless, both variants continue
to form abscesses [5]. Of note, a clfA/clfB double mutant has not
yet been examined for its ability to form abscesses. Three
additional secreted factors of S. aureus, Efb (extracellular fibrinogen
binding protein), Efb-h and Eap bind fibrinogen or fibrin and do
so without clotting [47,48,49]. One of these, Eap, has been
demonstrated to contribute to disease pathogenesis and antibodies
against Eap generate a moderate amount of protection against
Figure 6. Contribution of coagulase specific antibodies towards the survival of mice with staphylococcal bacteremia. Twenty-four
hours prior to infection, BALB/c mice (n=10) were injected into the peritoneum with purified rabbit antibodies (5 mg antibody/kg body weight).
Animals were then challenged with 1610
8 CFU S. aureus Newman (A) or 5610
7 CFU S. aureus USA300 LAC (B) injected into the retro-orbital plexus
and monitored for survival. Data are representative of two independent experiments.
doi:10.1371/journal.ppat.1001036.g006
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different factors that decorate the bacterial surface with fibrinogen
or promote staphylococcal binding to fibrin and platelet clots. We
surmise that during bloodstream infections, Coa and vWbp
promote establishment of microthrombi, thereby disrupting local
bloodflow and promoting staphylococcal adhesion to the vascu-
lature. Endothelial cells in association with staphylococci would
thus be exposed to high concentrations of toxins, precipitating
local injury and inflammation. These events may ultimately
promote colonization and staphylococcal invasion across blood
vessels and into organ tissues. These predictions can now be tested
to unravel the many unique attributes of coagulases towards the
pathogenesis of staphylococcal diseases.
Nucleotide sequence specifying the D1 domain of coagulase
displays variation between different staphylococcal isolates,
providing the basis for classification of S. aureus into twelve
clusters, each with more than 90% coa nucleotide identity among
its members [50]. Origins of this variation are thought to be
recombinational events between the repeat sequences of coa,
resulting in 50% sequence diversity in the D1 domain [50]. This
variation also underwrites staphylocoagulase serotyping, i.e. the
ability of type-specific human immunoglobulins to neutralize
coagulases of corresponding types [51]. It is not known whether
the recently reported D1 sequence variation can provide for an
escape from protective immunity afforded by coagulase-specific
antibodies as is reported here. Future work will need to define the
molecular basis of protective immunity by Coa and vWbp specific
immune responses and address the scope of protection against the
different coagulase types of S. aureus isolates.
Materials and Methods
Ethics statement
Experiments with blood from human volunteers involved a
protocol that was reviewed, approved and performed under the
regulatory supervision of The University of Chicago’s Institutional
Review Board (IRB). Written, informed consent was provided by
all volunteers. Experimental protocols were reviewed, approved
and performed under regulatory supervision of The University of
Chicago’s Institutional Biosafety Committee (IBC) and Institu-
tional Animal Care and Use Committee (IACUC). Animals are
managed by the University of Chicago Animal Resource Center,
which is accredited by the American Association for Accreditation
of Laboratory Animal Care and the Department of Health and
Human Services (DHHS number A3523-01). Animals are main-
tained in accordance with the applicable portions of the Animal
Welfare Act and the DHHS ‘‘Guide for the Care and Use of
Laboratory Animals’’. Veterinary care is under the direction of
full-time resident veterinarians boarded by the American College
of Laboratory Animal Medicine.
The signs for judging morbidity have been specified by the
IACUC to be any one of the following: rapid respiration; slow,
shallow or labored respiration; rapid weight loss and ruffled fur;
hunched posture; inappetence. Signs for judging animals to be
moribund included any one of the following: signs of morbidity
plus; impaired ambulation; evidence for muscle atrophy or
emaciation; lethargy; inability to remain upright. Signs of pain
in infected animals were judged if any one of the following was
observed: animal not alert, abnormal postures or abnormal
movement; inappetence or dehydration; guarding reaction upon
contact; vocalization when palpated or moved; self-mutilation,
restlessness or lethargy; shock. Animals that were judged to be
moribund were euthanized with CO2, a method that is approved
by the Panel on Euthanasia of the American Veterinary Medical
Association.
Bacterial strains and growth of cultures
Staphylococci were cultured on tryptic soy agar or broth at
37uC. E. coli strains DH5a and BL21(DE3) [52] were cultured on
Luria agar or broth at 37uC. Ampicillin (100 mg/ml) and
chloramphenicol (10 mg/ml) were used for pET15b [52] and
pOS1 [30] plasmid selection, respectively.
Table 2. Passive immunization of mice with rabbit antibodies against Coa and/or vWbp and protection against S. aureus Newman
challenge.
Purified rabbit
antibody Staphylococcal load in kidney tissue* Abscess formation *
alog10 CFU g
21
of kidney tissue
bSignificance
(P-value)
cReduction in
alog10 CFU g
21d IgG Titer
eNumber of abscesses
per kidney
fSignificance
(P-value)
Mock 5.8660.88 – – ,0.1 4.661.4 –
avWbp 5.2561.07 0.355 0.60 1.160.2 1.460.5 0.016
aCoa 4.6861.42 0.042 1.18 1.360.25 1.260.7 0.030
avWbp/Coa 4.2961.58 0.013 1.53 160.3/
1.2460.13
0.360.2 0.004
*BALB/c mice (n=10, 2 repeat trials) were injected into the peritoneum with 100 ml each of affinity purified rabbit antibodies against vWbp (avWbp), Coa (aCoa) or
vWbp and Coa (avWbp/Coa) on day 0. Twenty four hours later, 3 animals per cohort were examined for IgG antibody titers in serum and the mice were challenged by
intravenous inoculation with 1610
7 colony forming units (CFU) S. aureus Newman. Five days later, animals were killed and both kidneys removed. One kidney was fixed
in formaldehyde, embedded in paraffin, thin sectioned, hemaotoxylin-eosin stained and four saggital sections per kidney were analyzed for abscess formation. The
other kidney was homogenized in PBS buffer, homogenate spread on agar medium for colony formation, and staphylococcal load enumerated as CFU. This experiment
was performed twice, and the data are an average of the two trials.
aMeans of staphylococcal load calculated as log10 CFU g
21 in homogenized renal tissues 5 days following infection in cohorts of 10 BALB/c mice per immunization.
Standard error (6SE) is indicated.
bStatistical significance was calculated with the unpaired two-tailed Students t-test and P-values recorded; P-values ,0.05 were deemed significant.
cReduction in bacterial load calculated as log10 CFU g
21.
dAntibody titers were analyzed by ELISA with purified recombinant antigen (1 mgm l
21) by dilution of serum. Indicated values are in thousands.
eHistopathology of thin-sectioned, hematoxylin-eosin stained kidneys from ten animals; the average number of abscesses per kidney was recorded and averaged again
for the final mean (6SEM).
fStatistical significance was calculated with the non-parametric Mann-Whitney test and P-values recorded; P-values ,0.05 were deemed significant.
doi:10.1371/journal.ppat.1001036.t002
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DNA sequences 1 kb upstream and downstream of coa and
vWbp were PCR amplified using the primers attB1_Coa,
Coa1_BamHI, Coa2_BamHI, attbB2_Coa and attB1_vWF,
vWF1_BamHI, vWF2_BamHI, attbB2_vWF (Table S1). The
fragments were exchanged onto pKOR1 using the BP clonase II
kit (Invitrogen) [29]. These vectors were electroporated into S.
aureus Newman and subjected to temperature shift induced allelic
exchange to generate the corresponding deletion [29]. Mutants
were verified by PCR amplification of the gene locus, DNA
sequencing, and immunoblot analysis.
To generate complementing plasmids, the primers Coa_pro-
moter_BamHI_F, Coa_out_PstI_R, vWbp_promoter_BamHI_F,
vWbp_out_PstI_R (Table S1) were designed to include the
upstream promoter region of vWbp or coa and the amplified
regions were cloned into pOS1. Plasmid pcoa did not restore the
expression of Coa to wild-type levels (Fig. 2B). Therefore, the
primer Coa_promoter_x2_BamHI (includes 200 bp upstream of
coa) was used to generate the plasmid pcoa-vWbp (Fig. S4A).
Plasmids constructs were verified by DNA sequencing and
electroporated into staphylococcal strains. For immunoblot
analysis, overnight cultures of staphylococci grown in tryptic soy
broth (Difco) were refreshed 1:100 and grown with shaking at
37uC until they reached OD600 of 0.4. One ml samples of each
culture were centrifuged at 13,0006g for 10 min in a table top
centrifuge and the supernatant was recovered. Trichloroacetic
acid, 75 ml of 100% w/v solution, was added and samples were
incubated on ice for 10 min, followed by centrifugation and
washing of the sediment with 1 ml ice-cold 100% acetone.
Samples were air dried overnight and solubilized in 50 ml sample
buffer (4% SDS, 50 mM Tris-HCl, pH 8.0, 10% glycerol, and
bromophenol blue).
Animal experiments
BALB/c mice and New Zealand white rabbits were purchased
from Charles River Laboratories. After confirming that the data
Figure 7. Passive transfer of coagulase antibodies confers protection against S. aureus abscess formation. An experimental mock (PBS,
A and C) or purified rabbit antibodies directed against vWbp (avWbp, B and D), Coa (aCoa, E and G) or both coagulases (aCoa/avWbp, F and H) were
injected into the peritoneal cavity of BALB/c mice (n=10) and antibody titers analyzed by ELISA (Table 2). Passively immunized animals were infected
by injecting 1610
7CFU S. aureus Newman into the retro-orbital plexus. Bacterial load and abscess formation were determined following necropsy in
the kidneys of animals that had been killed five days following infection. Renal tissues were fixed, thin-sectioned, stained with hematoxylin-eosin and
histopathology images acquired by light microscopy. Data are representative of two separate experiments.
doi:10.1371/journal.ppat.1001036.g007
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staphylococcal burden in renal tissue was analyzed using the
unpaired two-tailed student’s t-test. Quantification of mouse renal
abscesses in histopathology slides were analyzed for statistical
significance using the non-parametric Mann-Whitney test. Statis-
tical significance of the mouse lethal challenge data was calculated
with the two-tailed log-rank test. All animal experiments were
conducted at least twice to assess reproducibility.
Blood survival assay and blood coagulation
Overnight cultures of staphylococcal strains were diluted 1:100
into fresh TSB and grown at 37uC until they reached an OD600 0.4.
One ml of culture was centrifuged, and staphylococci washed and
suspended in 10 ml of sterile PBS to generate a suspension of 1610
7
CFU/ml. Whole blood from naı ¨ve 6 week old BALB/c mice was
collected and refludan (lepirudin, Bayer) was added to a final
concentration 50 mg/ml. 450 mL blood was aliquoted into a 1 ml
eppendorf tube and mixed with 50 ml bacterial sample (1610
5
CFU/ml). Samples were incubated at 37uC with slow rotation.
100 ml aliquotswereremovedattimes0 minand30 min,mixed1:1
with 2% saponin/PBS and incubated on ice for 30 minutes. Five
1:10 serial dilutions were prepared and 10 ml aliquots spread on
TSA agar for colony formation and enumeration.
To assess bacterial blood coagulating activity, 10 ml of the above
stock bacterial culture was added to 100 ml of anti-coagulated
mouse blood in a sterile plastic test tube (BD falcon) to achieve a
final concentration of 1610
5 CFU/ml. For antibody perturbation,
an additional 10 ml of PBS containing 3610
25 Mol of antibody was
added to the mixture. To assess recombinant proteins, 10 mlo f
protein in PBS buffer added to a final concentration of 50 mM. Test
tubes were incubated at room temperature and blood coagulation
was verified by tipping the tubes to 45u angles at timed intervals.
Consenting human volunteers were bled by venous puncture for
10 ml of blood, which was treated with lepirudin to a final
concentration of 50 mg/ml. Blood samples were then tested in the
manner described above for mouse blood. All experiments were
repeatedinatleastthreeindependenttrialstoexaminereproducibility.
Protein purification
For vaccination studies, full-length coding sequence of mature
Coa or vWbp was cloned into pET15b vector using the primers
Coa_foward_XhoI, Coa_reverse_BamHI, vWbp_forward_XhoI,
vWbp_reverse_BamHI (Table S1) to obtain His6-Coa and His6-
vWbp. E. coli BL21(DE3) harboring expression vectors were grown
at 37uC and induced with 1 mM IPTG after two hours. Four hours
following induction, cells were centrifuged at 6,0006g, supended in
16column buffer (0.1 M Tris-HCl pH 7.5, 0.5 M NaCl) and lysed
in a French press at 14,0000 lb/in
2. Lysates were subjected to
ultracentrifugation at 40,0006g for 30 min and the supernatant was
subjected to Ni-NTA chromatography, washed with column buffer
containing 25 mM imidazole,followed by elution with 500 mM
imidazole. Eluates were dialyzed against 16PBS. To remove
endotoxin, 1:1,000 Triton-X114 was added and the solution was
chilled for 5 min, incubated at 37uC for 10 min, and centrifuged at
13,0006g. Supernatant was loaded onto a HiTrap desalting column
to remove remnants of Triton-X114.
Table 3. Active immunization of mice with Coa and/or vWbp and protection against S. aureus Newman challenge.
Purified vaccine
antigen Staphylococcal load in kidney tissue* Abscess formation*
alog10 CFU g
21
kidney tissue
bSignificance
(P-value)
cReduction in
alog10 CFU g
21d IgG Titer
eNumber of abscesses
per kidney
fSignificance
(P-value)
Day 5 post challenge
Mock 5.6561.03 – – ,0.1 2.360.8 –
vWbp 4.8961.22 0.055 0.76 1465 1.460.4 0.524
Coa 4.4561.69 0.018 1.20 1964 0.460.2 0.010
vWbp/Coa 4.8361.14 0.034 0.82 761.5/
7.2561.03
0.360.2 0.006
Day 15 post challenge
Mock 6.1660.93 – – ,0.1 4.060.7 –
vWbp 4.2261.46 4.25610
25 1.94 1465 2.060.4 0.057
Coa 3.9061.43 6.42610
26 2.26 1964 1.360.5 0.005
vWbp/Coa 3.7961.12 5.15610
26 2.37 761.5/
7.2561.03
0.660.2 0.001
*BALB/c mice (n=10, 2 repeat trials) were injected with 50 mg each of purified vWbp, Coa or vWbp and Coa emulsified in CFA on day 0 and boosted with the same
antigen emulsified in IFA on day 11. On day 20, 3 animals per cohort were examined for IgG antibody titers and on day 21 the mice were challenged by intravenous
inoculation with either 1610
7 colony forming units (CFU) S. aureus Newman. On day 25 (day 5 post challenge) or 35 (day 15 post challenge), animals were killed and
both kidneys removed. One kidney was fixed in formaldehyde, embedded in paraffin, thin-sectioned, hemaotoxylin-eosin stained and four saggital sections per kidney
were analyzed for abscess formation. The other kidney was homogenized in PBS buffer, homogenate spread on agar medium for colony formation, and staphylococcal
load enumerated as CFU. This experiment was performed twice, and the data are an average of the two trials.
aMeans of staphylococcal load calculated as log10 CFU g
21 in homogenized renal tissues 5 or 15 days following infection in cohorts of 10 BALB/c mice per immunization.
Standard error (6SE) is indicated.
bStatistical significance was calculated with the unpaired two-tailed Students t-test and P-values recorded; P-values ,0.05 were deemed significant.
cReduction in bacterial load calculated as log10 CFU g
21.
dMeans of five randomly chosen serum IgG titers were measured prior to staphylococcal infection by ELISA with purified recombinant antigen (1 mgm l
21) by dilution of
serum. Indicated values are in thousands.
eHistopathology of thin-sectioned, hematoxylin-eosin stained kidneys from ten animals; the average number of abscesses per kidney was recorded and averaged again
for the final mean (6SEM).
fStatistical significance was calculated with the non-parametric Mann-Whitney test and P-values recorded; P-values ,0.05 were deemed significant.
doi:10.1371/journal.ppat.1001036.t003
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sequence of mature Coa or vWbp was cloned into pET15b with
primers Coa_Xho_factorXa_F, Coa_reverse_BamHI, vWbp_Xho_
factorXa_F, vWbp_reverse_BamHI (Table S1) which contain a
Factor Xa site preceding the initial Ile-Val-Thr-Lys of coagulase and
Val-Val-Ser-Gly of vWbp. These proteins were expressed and
purified using the above protocol, then cleaved with 10 units Factor
Xa/1ml for 1 hour at 25uCt or e m o v et h eH i s 6 tag from the N-
terminus. Proteins were then loaded onto a Superdex 75 (GE
Healthcare) column for final purification. All eluted proteins were
stored in 16PBS.
Rabbit antibodies
Protein concentration was determined using a BCA kit (Thermo
Scientific). Purity was verified by SDS page gel analysis and
Coomassie Brilliant Blue staining. Six month old New-Zealand
white female rabbits (Charles River Laboratories) were immunized
with 500 mg protein emulsified in CFA (Difco) for initial
immunization or IFA for booster immunizations on day 24 and
48. On day 60, rabbits were bled and serum recovered for
immunoblotting or passive transfer experiments. For antibody
purification, recombinant His6-Coa or His6-vWbp (5 mg) was
covalently linked to HiTrap NHS-activated HP columns (GE
Healthcare). This antigen-matrix was then used for affinity
chromatography of 10–20 ml of rabbit serum at 4uC. Charged
matrix was washed with 50 column volumes of PBS, antibodies
eluted with elution buffer (1 M glycine pH 2.5, 0.5 M NaCl) and
immediately neutralized with 1M Tris-HCl, pH 8.5. Purified
antibodies were dialyzed overnight against PBS at 4uC.
Surface plasmon resonance
Affinity and rates of association and dissociation were measured
on a BIAcore 3000. Buffers were sterile filtered and degassed. A
CM5 chip was prepared for amine linkage by injection of human
Figure 8. Immunization with coagulases protects mice against S. aureus abscess formation. BALB/c mice (n=10) were actively immunized
with an experimental mock (PBS, A and C), purified vWbp (50ug His6-vWbp, B and D), purified Coagulase (50 mg His6-Coa, E and G), or a combination
of the two proteins (50ug each His6-vWbp and His6-coa, F and H) emulsified with adjuvant on day 0. Mice were boosted on day 11 and antibody titers
analyzed by ELISA on day 21 (Table 3). On day 21, animals were challenged by injecting 1610
7CFU S. aureus Newman into the retro-orbital plexus.
Bacterial load and abscess formation were determined following necropsy in the kidneys of animals that had been killed five days following infection.
Renal tissues were fixed, thin-sectioned, stained with hematoxylin-eosin and histopathology images acquired by light microscopy. Data are
representative of two separate experiments.
doi:10.1371/journal.ppat.1001036.g008
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fibrinogen (200 nM, pH 4.5) (Innovative Research) in presence of
0.2 M EDC and 0.05 M NHS. To measure the interaction of
coagulase with prothrombin and fibrinogen, Coa was diluted into
HBS-P buffer (20 mM HEPES [pH 7.4], 150 mM NaCl, 0.005%
[vol/vol] surfactant P20) at a range of concentrations. For the
coagulase-prothrombin interaction, coagulase was injected at
10 pM, 0.1 nM, 1 nM, 5 nM, 10 nM, 25 nM, and 50 nM for
300 seconds followed by 300 seconds of dissociation followed by
regeneration with NaOH (50 mL, 30 seconds). For the coagulase-
fibrinogen interaction, coagulase was injected at 100 pM, 500 pM,
1 nM, 5 nM, 10 nM, 25 nM, 50 nM, 100 nM, and 300 nM for
60 seconds of association followed by 60 seconds of dissociation
and the chip was regenerated as described above. To assess vWbp-
prothrombin and vWbp-fibrinogen interactions, vWbp was
injected at 1 nM, 10 nM, 50 nM, 100 nM, 500 nM, and 1 mM
for 60 seconds followed by 60 seconds of dissociation and
regeneration. All injections were performed with a flow rate of
2 mL/min. Kinetic coefficients, KD, and x
2 were determined using
the BiaEvaluation software and best fit was determined with a 1:1
binding model with drifting baseline and local Rmax. All
experiments were repeated in triplicate on at least three occasions.
Blocking protein interactions by ELISA
MaxSorb 96-well ELISA plates were coated with recombinant
coagulase and vWbp (5 mg/mL in 16coating buffer) overnight.
Wells were then incubated with the corresponding purified
antibodies at 1:1000, 1:100, and 1:10 dilutions, PBS-BSA 1%, or
1:10 dilution of purified antibodies against V10 protein. Wells were
subsequently incubated with either 5 mM human fibrinogen or
1 mM human prothrombin. Sheep-anti-human antibodies against
the respective proteins were added at 1:1000 dilution followed by
HRP-conjugated goat-anti-sheep antibody at 1:10,000. The wells
were developed using an OptEIA kit (BD Lifesciences) and
absorbance at 450 nm was measured. Two-tailed t- tests were used
to determine statistically significant differences between the means
of binding observations in the presence or absence of antibodies.
Measurements of coagulase activity
1610
216 M prothrombin (Innovative Research) was pre-incu-
bated for 20 min with an equimolar amount of functional Coa or
vWbp at room temperature, followed by addition of S-2238 (a
chromogenic substrate) to a final concentration of 1 mM in a total
reaction buffer of 100 ml1 6PBS. The change in absorbance was
measuredat450 nmfor10 minutesinaspectrophotometer,plotted
as a function of time, and fit to a linear curve. The slope of the curve
(dA/dt) was interpreted to be the rate of S-2238 hydrolysis, and thus
reflective of enzymatic function(% Coa?prothrombin or vWbp?pro-
thrombin complex activity). The assay was repeated in presence of
specific antibodies added at 3610
216M and data were normalized
to the % average activity without inhibition.
Renal abscess model and lethal challenge
Overnight cultures of staphylococcal strains were diluted 1:100
into fresh TSB and grown until they reached an OD600 of 0.4.
Bacteria werecentrifugedat 7,5006g, washed, and suspended inthe
Table 4. Active immunization of mice with Coa and/or vWbp and protection against S. aureus USA300 challenge.
Purified vaccine
antigen Staphylococcal load in kidney tissue* Abscess formation*
alog10 CFU g
21
kidney tissue
bSignificance
(P-value)
cReduction in
alog10 CFU g
21d IgG Titer
eNumber of abscesses
per kidney
fSignificance
(P-value)
Day 5 post challenge
Mock 6.4460.34 – – ,0.1 4.060.9 –
vWbp 5.2560.93 0.285 1.19 14.564.6 2.360.6 0.042
Coa 6.2960.50 0.814 0.15 19.764.5 2.160.4 0.074
vWbp/Coa 6.1660.53 0.678 0.28 12.763.4/
25.963.1
0.860.5 0.022
Day 15 post challenge
Mock 5.6160.29 – – ,0.1 3.260.6 –
vWbp 3.6760.74 0.052 1.94 14.564.6 2.460.7 0.111
Coa 5.1960.72 0.472 0.42 19.764.5 1.960.4 0.449
vWbp/Coa 2.8260.69 0.006 2.79 12.763.4/
25.963.1
0.860.3 0.014
*BALB/c mice (n=10) were injected with 50 mg each of purified vWbp, Coa or vWbp and Coa emulsified in CFA on day 0 and boosted with the same antigen emulsified
in IFA on day 11. On day 20, 3 animals per cohort were examined for IgG antibody titers and on day 21 the mice were challenged by intravenous inoculation with 5610
6
colony forming units (CFU) S. aureus USA300. On day 25 (day 5 post challenge)or 35 (day 15 post challenge), the mice were sacrificed both kidneys removed. One kidney
was fixed in formaldehyde, embedded in paraffin, thin-sectioned, hemaotoxylin-eosin stained and four saggital sections per kidney were analyzed for abscess formation.
The other kidney was homogenized in PBS buffer, homogenate spread on agar medium for colony formation, and staphylococcal load enumerated as CFU. This
experiment was performed twice, and the data are an average of the two trials.
aMeans of staphylococcal load calculated as log10 CFU g
21 in homogenized renal tissues 5 or 15 days following infection in cohorts of 10 BALB/c mice per immunization.
Standard error (6SE) is indicated.
bStatistical significance was calculated with the unpaired two-tailed Students t-test (t-test) and P-values recorded; P-values ,0.05 were deemed significant.
cReduction in bacterial load calculated as log10 CFU g
21.
dMeans of five randomly chosen serum IgG titers were measured prior to staphylococcal infection by ELISA with purified recombinant antigen (1 mgm l
21) by dilution of
serum. Indicated values are in thousands.
eHistopathology of thin-sectioned, hematoxylin-eosin stained kidneys from ten animals; the average number of abscesses per kidney was recorded and averaged again
for the final mean (6SEM).
fStatistical significance was calculated with the non-parametric Mann-Whitney test and P-values recorded; P-values ,0.05 were deemed significant.
doi:10.1371/journal.ppat.1001036.t004
Coagulases as Protective Antigens
PLoS Pathogens | www.plospathogens.org 15 August 2010 | Volume 6 | Issue 8 | e1001036same volume of 16PBS. Six week-old female BALB/c mice
(Charles River) were injected retro-orbitally with 1610
7 CFU
(Newman) or 5610
6 CFU (USA300) suspensions in 100 mlo fP B S
using cohorts of 10 mice. On the fifth or fifteenth day post infection,
mice were killed by CO2 asphyxiation and their kidneys excised. All
organs were examined for surface lesions and 8–10 right kidneys
were sent for histopathology sectioning and hematoxylin-eosin
staining. These slides were examined by light microscopy for
internal abscesses. For the lethal challenge model, all experimental
conditions remain the same except that 1610
8 CFU (Newman) or
5610
7 CFU (USA300) were administered and that the mice were
monitored for survival over 10 days post infection.
Immuno-histochemistry staining of renal sections
Sectioned kidneys were deparaffinized and rehydrated through
xylen and serial dilutions of ethanol to distilled water. Samples
were incubated in antigen retrieval buffer (DAKO, pH 6.0) and
heated in steamer oven at 96uC for 20 minutes. After rinsing, the
slides were incubated in 3% hydrogen peroxide for 5 minutes and
then 10% normal serum in 0.025%Triton X-100 -PBS for
30 minutes. 10% human IgG was used as blocking reagent for
30 minutes incubation (Sigma-Aldrich). Primary antibody was
applied to the slides for overnight incubation at 4uC degree in a
humidity chamber. The primary antibodies used were 1:500 rat
anti-mouse Prothrombin (Innovative Research), 1:500 rabbit anti-
mouse fibrinogen (Innovative Research), 1:250 rabbit aCoa, or
1:250 rabbit avWbp. Following TBS wash, the slides were
incubated with biotinylated secondary antibody (1:50 dilution of
biotinylated anti-rat IgG, BA-4001 from Vector Laboratories; or
1:200 dilution of biotinylated anti-rabbit IgG, BA-1000 from
Vector), and then ABC reagents (Vector Laboratories). Antigen-
antibody binding was detected with the DAB substrate chromogen
system. The slides were briefly immersed in hematoxylin for
counterstaining and evaluated by light microscopy.
Active immunization
Three week old BALB/c mice were injected with 50 mg protein
each emulsified in 100 ml CFA. Cohorts of 10 mice were used,
with 3 mice reserved for bleeding and antibody titers. Eleven days
post vaccination these mice were boosted with 50 mg protein each
emulsified in 100 ml IFA. On day 21, mice were injected with
1610
7 CFU (Newman - renal abscess model, 1610
8 CFU
(Newman – lethal challenge/septicemia) or 5610
7 CFU
(USA300- lethal challenge/septicemia).
Passive transfer of antibodies
Twenty-four hours prior to infection, six week old BALB/c mice
were injected with affinity purified antibodies against Coa and/or
vWbp at a dose of 5mg/kg body weight. Cohorts of 10 mice were
used. These mice were challenged by retro-orbital injection with
1610
7 CFU (Newman - renal abscess model) or 1610
8 CFU
(Newman – lethal challenge/septicemia) or 5610
7 CFU (USA300
– lethal challenge/septicemia).
S. aureus Newman Coagulase
Gene ID: 5330026
Protein reference sequence: YP_001331201.1
S. aureus Newman von Willebrand factor binding protein
Gene ID: 5331820
Protein reference sequence: YP_001331791.1
Supporting Information
Figure S1 Immunohistochemical staining with secondary anti-
body. BALB/c mice were infected by intravenous inoculation with
1610
7 CFU S. aureus Newman and killed 5 days post infection.
Kidneys were removed, embedded in paraffin, and, as a control to
Figure 1, thin-sections stained by immunochemistry using HRP-
conjugated (secondary) antibody alone. No specific staining of
tissues is observed.
Found at: doi:10.1371/journal.ppat.1001036.s001 (2.08 MB TIF)
Figure S2 S. aureus coa and vWbp mutants display defects in
clotting of and survival within human blood. (A) Lepirudin-
anticoagulated human blood was mock treated with PBS or
infected with S. aureus Newman, Dcoa, DvWbp or DvWbp/Dcoa and
the complemented variants incubated for up to 48 hours at 25uC.
Tubes were tilted to assess coagulation. Data are representative of
four independent determinations. (B) The same strains as above
were incubated with lepirudin-anticoagulated human blood for
30 minutes, upon which an aliquot was removed and plated.
Staphylococcal survival was assessed by colony formation on agar
and the counts were normalized against the initial CFU inoculum.
The data shown are an average of three separate trials, stars
indicate P,0.05.
Found at: doi:10.1371/journal.ppat.1001036.s002 (5.50 MB TIF)
Figure S3 Plasmid complementation of Dcoa and DvWbp mutant
phenotypes. (A) Plasmid pvWbp-coa, which contains both wild-type
coa and vWbp cloned into the vector pOS1, was electroporated into
the DvWbp/Dcoa variant of S. aureus Newman. Culture superna-
tants from S. aureus Newman (wt) or the DvWbp/Dcoa variant
containing pOS1 or pvWbp-coa were examined by immunoblotting
with aCoa or avWbp antibodies. (B) Cohorts of 10 mice were
injected into the retro-orbital plexus with 1610
8 CFU of the
aforementioned strains. The survival of infected mice was
recorded over 10 days. Data are representative of two independent
experimental trials.
Found at: doi:10.1371/journal.ppat.1001036.s003 (5.08 MB TIF)
Figure S4 Antibodies against Coa and vWbp block S. aureus
USA300 clotting of human blood. (A) Lepirudin-treated human
blood was treated with PBS (mock), irrelevant antibodies (aV10) or
antibodies directed against Coa (aCoa), vWbp (avWbp) or both
coagulases (aCoa/avWbp) prior to infection with S. aureus
Newman and incubation for 48 hours at 25uC. (B) Lepirudin-
treated human blood was treated with antibodies as above. Blood
samples were then incubated with functionally active Coa or
vWbp and coagulation time recorded.
Found at: doi:10.1371/journal.ppat.1001036.s004 (2.96 MB TIF)
Figure S5 Surface plasmon resonance measurements of the
association between staphylococcal coagulases and human coag-
ulation proteins. Purified Coa (A,B) and vWbp (C,D) were
covalently immobilized to a CM5 chip. Prothrombin (A, C) and
fibrinogen (B,D) were injected over the chip at increasing
concentrationso (shown in inset) and the response increase was
measured over time. The affinity was calculated by the kinetic data
using BiaEvaluation software (E) and the residual difference from
the fit are shown below the sensorgram.
Found at: doi:10.1371/journal.ppat.1001036.s005 (7.70 MB TIF)
Figure S6 Immunization with coagulases protects mice against
S. aureus USA300 abscess formation. BALB/c mice (n=10) were
immunized with 50 mg His6-Coa (E, G, M, O), His6-vWbp, (B, D,
J, L), His6-Coa and His6-vWbp (F, H, N, P) or PBS (mock, A, C, I,
K) emulsified with adjuvant on day 0 and 11 and antibody titers
analyzed by ELISA on day 21 (Table 4). On day 21, animals were
challenged by injecting 5610
6 CFU S. aureus USA300 LAC into
the retro-orbital plexus. Bacterial load and abscess formation were
determined following necropsy in the kidneys of animals that had
been killed five days (A–H) or fifteen days (I–P) following infection.
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and histopathology images acquired by light microscopy. Data are
representative of two separate experiments.
Found at: doi:10.1371/journal.ppat.1001036.s006 (8.93 MB TIF)
Figure S7 Immunization with coagulases protects mice against
S. aureus USA300 lethal bacteremia. BALB/c mice (n=10) were
immunized with 50 mg His6-Coa, His6-vWbp, His6-Coa and His6-
vWbp or mock (PBS) emulsified with adjuvant on day 0 and 11
and antibody titers were analyzed by ELISA on day 21 (Table 4).
On day 21, animals were challenged via the injection of 1610
8
CFU S. aureus USA300 LAC into the retro-orbital plexus. Animals
were monitored for survival up to 240 hrs after challenge.
Statistical significance was calculated via the log-rank test. Data
are representative of two independent experiments.
Found at: doi:10.1371/journal.ppat.1001036.s007 (3.10 MB TIF)
Table S1 Primers used in this study
Found at: doi:10.1371/journal.ppat.1001036.s008 (0.04 MB
DOC)
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